Drug Trial News

RSS

Oxford COVID-19 vaccine trials move to stage 3 human trials

The technical name of the vaccine is ChAdOx1 nCoV-19 (AZD1222), as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

5 Jul 2020

New editorial published following adverse events of gene therapy clinical trial

The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.

3 Jul 2020

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

In a recent medRxiv* paper, a research group from the U.S. and Germany showed a robust immunogenic response and a promising safety profile of the novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) – actively encouraging its accelerated clinical development and potential rapid production.

2 Jul 2020

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Breast cancer patients who are overweight or obese might benefit less from treatment with docetaxel, a common chemotherapy drug, than lean patients.

2 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

RCSI begins clinical trial of promising therapy for critically ill COVID-19 patients

Clinician scientists at RCSI University of Medicine and Health Sciences have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care.

29 Jun 2020

Combination therapy improves survival rates for women with aggressive endometrial cancer

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

29 Jun 2020

Chronic kidney disease medication doesn’t work, shows study

A major clinical trial from the University of New South Wales (UNSW) reports that a medication called allopurinol, which is prescribed to about 20% of patients with chronic kidney disease (CKD), doesn’t work as expected. The results are published in the New England Journal of Medicine on June 25, 2020.

28 Jun 2020

China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE

Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China’s vaccine is the first one to proceed to phase III human trials.

26 Jun 2020

Promising treatment does not guard against complication in type 1 diabetes

Historically, half or more of people with type 1 diabetes develop kidney disease, which frequently progresses to kidney failure requiring hemodialysis or a kidney transplant for survival.

25 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

International trial shows better option for treating people with inoperable anal cancer

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

24 Jun 2020

Members of Vivli announce commitment to share COVID-19 trial data

Members of Vivli, the Center for Clinical Research Data, announce today their commitment to share their COVID-19 trials through Vivli.

23 Jun 2020

Dexamethasone could benefit certain hospitalized COVID-19 patients

The RECOVERY Collaborative Group has released a preliminary report describing the effects of dexamethasone treatment among patients hospitalized with coronavirus disease 2019 (COVID-19).

23 Jun 2020

First clinical trial in South Africa for Covid-19 vaccine begins

The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

UTHealth tests arthritis drug's effect on COVID-19-induced cytokine storm

A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment.

22 Jun 2020